Considering the role of four months of rifampin in the treatment of latent tuberculosis infection

被引：41

作者：

Reichman, LB ^{[1
]}

Lardizabal, A ^{[1
]}

Hayden, CH ^{[1
]}

机构：

[1] Univ Med & Dent New Jersey, Natl Tuberculosis Ctr, Newark, NJ 07101 USA

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2004年 / 170卷 / 08期

关键词：

D O I：

10.1164/rccm.200405-584PP

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

In summary, with 2RZ having been curtailed due to toxicity, and because of adherence and other difficulties with the 9H regimen, there are several reasons for considering the use of 4R in the treatment of LTBI (Table 1). We argue that 4R is an effective, relatively nontoxic, affordable strategy that clinicians and program managers should consider for more widespread use in selected populations and settings to effectively and efficiently treat LTBI, thereby accelerating the decline of TB in their communities.

引用

页码：832 / 835

页数：4

共 50 条

[1] The role of four months of rifampicin in the treatment of latent tuberculosis infection
Davies, P
Ormerod, P
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 172 (04) : 509 - 509
[2] Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin
Lardizabal, Alfred
Passannante, Marian
Kojakali, Faysal
Hayden, Christopher
Reichman, Lee B.
CHEST, 2006, 130 (06) : 1712 - 1717
[3] Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
Menzies, D.
Adjobimey, M.
Ruslami, R.
Trajman, A.
Sow, O.
Kim, H.
Baah, J. Obeng
Marks, G. B.
Long, R.
Hoeppner, V.
Elwood, K.
Al-Jahdali, H.
Gninafon, M.
Apriani, L.
Koesoemadinata, R. C.
Kritski, A.
Rolla, V.
Bah, B.
Camara, A.
Boakye, I.
Cook, V. J.
Goldberg, H.
Valiquette, C.
Hornby, K.
Dion, M. -J.
Li, P. -Z.
Hill, P. C.
Schwartzman, K.
Benedetti, A.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (05): : 440 - 453
[4] Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis
Stout, JE
Engemann, JJ
Cheng, AC
Fortenberry, ER
Hamilton, CD
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (06) : 824 - 827
[5] Rifampin and pyrazinamide for treatment of latent tuberculosis infection - Is it safe?
Jasmer, RM
Daley, CL
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (06) : 809 - 810
[6] Responsible use of rifampin for the treatment of latent tuberculosis infection
Batt, Jane
Khan, Kamran
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (25) : E678 - E679
[7] Rifampin Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection
Fountain, Francis F.
Tolley, Elizabeth A.
Jacobs, Anna R.
Self, Timothy H.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2009, 337 (05): : 317 - 320
[8] Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings
Bastos, Mayara Lisboa
Campbell, Jonathon R.
Oxlade, Olivia
Adjobimey, Menonli
Trajman, Anete
Ruslami, Rovina
Kim, Hee Jin
Baah, Joseph Obeng
Toelle, Brett G.
Long, Richard
Hoeppner, Vernon
Elwood, Kevin
Al-Jahdali, Hamdan
Apriani, Lika
Benedetti, Andrea
Schwartzman, Kevin
Menzies, Dick
ANNALS OF INTERNAL MEDICINE, 2020, 173 (03) : 169 - +
[9] Rifampin and pyrazinamide for treatment of latent tuberculosis infection - Reply to Cook
McElroy, PD
Ijaz, K
Navin, TR
CLINICAL INFECTIOUS DISEASES, 2006, 42 (06) : 892 - 893
[10] Four months of rifampicin monotherapy for latent tuberculosis infection in children
Oh, Chi Eun
Menzies, Dick
CLINICAL AND EXPERIMENTAL PEDIATRICS, 2022, 65 (05) : 214 - 221

← 1 2 3 4 5 →